Polatuzumab vedotin/bendamustine/rituximab (pola-BR) in R/R diffuse large B cell lymphoma with hemophagocytic lymphohistiocytosis
We have treated a rare case of elderly relapsed/refractory (R/R) duffuse large B cell lymphoma (DLBCL) with hemophagocytic lymphohistiocytosis (HLH) and SARS-CoV-2 infection, which achieved complete response (CR) without lymphoma-related symptoms after polatuzumab vedotin/bendamustine/rituximab (pola-BR) treatment. To the best of our knowledge, this is the first report of R/R DLBCL with HLH and Covid-19 treated with pola-BR, and the patient is still alive at the time of report. We found that polatuzumab vedotin may have a potential therapeutic effect on HLH and Covid-19.
Authors
- Xiaomei Zhang (ORCID: https://orcid.org/0000-0001-7767-0553)
- Jieping Li (ORCID: https://orcid.org/0009-0005-1226-3451)
- Chongling Hu (ORCID: https://orcid.org/0000-0002-2129-6926)
- Qing Xiao (ORCID: https://orcid.org/0000-0002-2014-9959)
- Longrong Ran (ORCID: https://orcid.org/0009-0000-1725-7345)
- Chaoyu Wang (ORCID: https://orcid.org/0000-0001-9224-5061)
- Zailin Yang (ORCID: https://orcid.org/0000-0002-8587-975X)
- Bingling Guo
- Xi Quan
- Dehong Huang
- Yao Liu (ORCID: https://orcid.org/0009-0000-1843-0517)
Institutions
- Chongqing University (CN)
- Chongqing Cancer Hospital (CN)
Publication Details
- Journal
- Discover Medicine
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1007/s44337-024-00167-8
- Citations
- 1
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 0.24
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing
- Centre Scientifique et Technique du Bâtiment
- Fundamental Research Funds for the Central Universities